TENAYA THERAPEUTICS I

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

15 май 2025 18:00:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

13 май 2025 05:30:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

07 май 2025 13:05:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

24 апр 2025 11:07:47 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

31 мар 2025 07:00:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

24 мар 2025 05:30:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session

19 мар 2025 05:30:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

10 мар 2025 13:05:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Pricing of Public Offering

03 мар 2025 20:19:31 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Proposed Public Offering

03 мар 2025 13:10:10 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

03 мар 2025 05:00:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

03 фев 2025 05:30:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

13 янв 2025 06:16:36 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

17 дек 2024 04:00:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

16 дек 2024 13:30:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

25 ноя 2024 05:30:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

19 ноя 2024 05:00:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

06 ноя 2024 13:05:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

17 окт 2024 13:30:00 Источник Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

03 сен 2024 05:30:00 Источник Nasdaq GlobeNewswire